Everest Medicines Limited

China’s retaliatory tariffs mean the option of manufacturing US-originated drugs in China is making more sense than ever, at least to some local partners of US pharmaceutical companies. China imposed

Asahi Kasei Corporation aims to build on the US presence it established and the health care business growth it jumpstarted when it bought Veloxis Pharmaceuticals A/S by paying approximately $1.1bn

Calliditas Therapeutics AB 's bid to get a second asset across the regulatory finishing line – following its immunoglobulin A nephropathy (IgAN) treatment Tarpeyo – seems to have been boosted despite

The month of March will bring eight more chances for the US FDA to approve novel drugs and biologics, potentially providing a corrective to 2024’s slow start for innovative approvals. The number of us